Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
RayzeBio, Inc. - Common Stock
(NQ:
RYZB
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
62.49 (10)
Ask (Size)
62.54 (3)
Prev. Close
62.49
Today's Range
N/A - N/A
52wk Range
22.14 - 62.51
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
March 19, 2024
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer...
Via
Benzinga
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
February 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Performance
More News
Read More
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
February 12, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio
December 26, 2023
Via
Benzinga
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
February 12, 2024
From
Bristol Myers Squibb
Via
Business Wire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
February 07, 2024
Via
FinancialNewsMedia
The Best-Performing U.S. IPOs Of 2023
February 04, 2024
Via
Talk Markets
IPO watch 2024: Which new stocks will hit the market?
January 08, 2024
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Via
Investor's Business Daily
Cramer Says This 'Inexpensive' Stock Is 'Doing Some Great Things With Aerospace'
January 05, 2024
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
January 04, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
December 31, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Via
MarketBeat
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
December 29, 2023
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
Via
Benzinga
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
December 27, 2023
Via
Benzinga
Investor Sentiment Improves; Dow Jumps Over 150 Points
December 27, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
December 26, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher
December 26, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 26, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 26, 2023
Via
Benzinga
Stocks Extend Gains As Oil Prices Rise
December 26, 2023
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
December 26, 2023
Via
Investor's Business Daily
Why Is RayzeBio (RYZB) Stock Up 100% Today?
December 26, 2023
Via
InvestorPlace
RYZB Stock Alert: Halper Sadeh LLC Is Investigating RayzeBio, Inc.
December 26, 2023
From
Halper Sadeh LLC
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
